Thomas G. Burger

MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA

BioDuro LLC provides research and development services for the life science industry. It offers services in the areas of chemistry, discovery biology, drug metabolism and pharmacokinetics and pharmacology, as well as integrated preclinical research and development. The company was founded by Masood K. Tayebi and John V. Oyler in 2005 and is headquartered in San Diego, CA.

Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Part of Incyte Corp., Maxia Pharmaceuticals, Inc. develops pharmaceutical products based on molecule drug discovery techniques. The company is based in San Diego, CA. The company was founded by David Perryman, Xian Ping Lu. Maxia Pharmaceuticals was acquired by Incyte Corp. on February 19, 2003 for $42.30 million.

Ortho Biotech Products LP provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses. The company's products include PROCRIT, DOXIL and LEUSTATIN. Ortho Biotech Products was founded in 1990 and is headquartered in Bridgewater, NJ

Beth Israel Deaconess Medical Center provides medical services. It offers patient care, biomedical research, teaching, and community services. It also provides organ transplantation, breast cancer care, and cardiac surgery services. The company was founded in 1896 and is headquartered in Boston, MA.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Translational Genomics Research Institute operates as non-profit organization. It focuses on developing earlier diagnoses and smarter treatments. Translational research applies to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company was founded by Jeffrey M. Trent in 2002 and is headquartered in Phoenix, AZ.

Part of Informedix Holdings, Inc., Informedix, Inc. develops portable and patient-based telehealth technology. The company is based in Rockville, MD.

Bionor Immuno AS engages in the research and development of biomedicine. It also owns and manages shares and other securities. The company was founded on July 14, 2000 and is headquartered in Oslo, Norway.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Part of Neumora Therapeutics, Inc., Alairion, Inc. is a company that develops novel chemo-protective medicinal products. The company is based in Cambridge, MA. Alairion was acquired by Neumora Therapeutics, Inc. on October 07, 2021.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.